Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 2, 2006, Pages 389-394

  Stock, Richard G ^a   Ho, Alice ^a   Cesaretti, Jamie A ^a   Stone, Nelson N ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; distant metastases; High risk; Local control; Prostate cancer

Indexed keywords

ANTIGENS; BIOLOGICAL ORGANS; BIOPSY; OPTIMIZATION; PATIENT TREATMENT;

BRACHYTHERAPY; LOCAL CONTROL; PROSTATE CANCER;

ONCOLOGY;

ANTIANDROGEN; GONADORELIN AGONIST; HORMONE; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SEMINAL VESICLE; SURVIVAL TIME; TREATMENT FAILURE;

ANDROGEN ANTAGONISTS; BIOPSY; BRACHYTHERAPY; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS; TREATMENT FAILURE;

EID: 33748312041     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.072     Document Type: Article

References (26)

1. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
2. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
3. Grossfeld G.D., Latini D.M., Lubeck D.P., et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 169 (2003) 157-163
4. Manoharan M., Bird V.G., Kim S.S., et al. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8. BJU Int 92 (2003) 539-544
5. van den Ouden D., Hop W.C., and Schroder F.H. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160 (1998) 1392-1397
6. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 247-252
7. Lerner S.E., Blute M.L., and Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: Outcome and contemporary morbidity. J Urol 154 (1995) 1447-1452
8. Stock R.G., Cahlon O., Cesaretti J.A., et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1352-1359
9. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2005) 527-533
10. Fleming I.D., and Cooper J.S. AJCC 1992 staging system (1997), Lippincott-Raven, Philadelphia
11. Stock R.G., Stone N.N., Ianuzzi C., et al. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: Implications for patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys 33 (1995) 815-819
12. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32 (1995) 219-225
13. Stock R.G., Stone N.N., and Lo Y.C. Intraoperative dosimetric representation of the real-time ultrasound guided prostate implant. Tech Urol 6 (2000) 95-98
14. Stock R.G., and Stone N.N. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. Brachytherapy 1 (2002) 2-10
15. Stone N.N., Stock R.G., and Unger P. Seminal vesicles: diagnosis, staging, surgey and management. In: Ritche J., and DAmico A. (Eds). Urologic oncology (2005), Elsevier-Saunders, Philadelphia 555-564
16. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
17. Norusis M.J. SPSS 10.0 guide to data analysis (2000), Prentice-Hall, Upper Saddle River, NJ
18. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
19. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A Phase III randomised trial. Lancet 360 (2002) 103-106
20. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
21. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
22. Hanks G.E., Pajak T.F., Porter A., et al., Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
23. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvis versus prostate only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
24. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
25. D'Amico A.V., Moul J., Carroll P.R., et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) 42-46
26. Lee W.R., Hanks G.E., and Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol 15 (1997) 230-238